MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies

The MDM2 gene is amplified in dedifferentiated liposarcoma (DDLPS). Treatment with MDM2 antagonists is a promising strategy to treat DDLPS; however, drug resistance is a major limitation when these drugs are used as a single agent. This study examined the impact of MDM2 antagonists on the mitogen-ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Shomereeta, Laroche-Clary, Audrey, Verbeke, Stephanie, Derieppe, Marie-Alix, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465494/
https://www.ncbi.nlm.nih.gov/pubmed/32806555
http://dx.doi.org/10.3390/cancers12082253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465494/
https://www.ncbi.nlm.nih.gov/pubmed/32806555
http://dx.doi.org/10.3390/cancers12082253

Ejemplares similares